Objective: To report our experience on the outcomes of ex vivo ureteroscopy and ex vivo pyelolithotomy carried out on the donor kidney before living donor renal transplantation. Methods: Between 2009 and 2016, 13 stone-bearing donor kidneys underwent ex vivo bench surgery after donor nephrectomy. Of these, six patients underwent ex vivo ureteroscopy and seven patients underwent ex vivo pyelolithotomy. Data were analyzed for technical feasibility, intraoperative and postoperative complications, stone clearance, and stone recurrence. Results: The mean stone burden was 9.1 mm (range 5-15 mm). Renal collecting system access and stone extraction were successfully achieved, and a stone-free status was accomplished with both techniques. The mean duration of ex vivo ureteroscopy was 12.5 min (range 9-20 min), and the mean duration of ex vivo pyelolithotomy was 3.1 min (range 1-8 min). One patient in the pyelolithotomy group developed urinary leakage and underwent surgical repair on the third postoperative day. The mean long-term follow-up duration was 49.6 months (range 14-101 months). None of the 13 patients included in the study suffered from stone recurrence. Conclusions: Our experience suggests that both ex vivo ureteroscopy and ex vivo pyelolithotomy procedures can safely and effectively be carried out in stone-bearing living donor kidneys, without compromising renal allograft function.
Introduction
RT is the best option for treating patients with end-stage renal disease, providing better physical, socioeconomic and psychological outcomes. 1 For a successful RT, it is important to select the appropriate donor. Although many guidelines have attempted to define the criteria for donor selection, there is still no consensus, and the management of donor kidney lithiasis is a controversial issue. Lithiasis in the donor kidney has been considered a relative contraindication to donation. As clearly stated in the Amsterdam forum in 2005, an asymptomatic potential donor with a current single stone might be considered suitable for kidney donation if: (i) there is no hypercalciuria, hyperuricemia or metabolic acidosis; (ii) there is no cystinuria or hyperoxaluria; and (iii) the current stone is <15 mm in size or potentially removable during transplant. 2 In such donors, the management of stones is a critical issue, because lithiasis in the transplanted kidney can cause obstruction, sepsis and loss of allograft function. However, the optimal treatment for such patients has not yet been determined. Some authors recommend watchful waiting for stones <4 mm. 3, 4 According to the limited literature on the management of stones with a diameter of 4-15 mm, some authors choose to carry out ESWL/RIRS before transplantation, 5, 6 whereas some authors prefer to carry out ex vivo stone surgery immediately after donor nephrectomy, which is known as ex vivo bench surgery. [7] [8] [9] We report our surgical experience and follow-up results in a series of renal transplant patients in whom the donor kidney underwent ex vivo bench surgery before transplantation.
Methods
After institutional review board approval was obtained (approval number: 004/2017), a retrospective study was undertaken to identify patients who had received living donor kidneys that underwent ex vivo stone removal on the back table before transplantation. All donors had undergone standard donor evaluation. The 24-h urinalyses of all donors were noted to be free of metabolic risk factors for urolithiasis, such as hypercalciuria, hypocitraturia, hyperuricosuria and hyperoxaluria. The screening results for other metabolic risk factors including gout, hyperparathyroidism and hypophosphatemia were also negative. All donors and recipients were informed in detail about the potential risks of developing nephrolithiasis in a solitary kidney after the transplantation period. Ex vivo bench surgery was carried out in donor kidneys with 4-15-mm stones confirmed by computed tomography angiography. Patients with asymptomatic stones <4 mm were not treated with ex vivo bench surgery. Instead, a JJ stent was inserted and the kidney was transplanted with the calculus in situ. For this reason, patients with stones <4 mm were excluded from the study. The demographic data (including age and sex), location of stone, stone size, surgical technique used, duration of operation, intraoperative and postoperative complications, stone-free status, stone recurrence in recipients, and renal allograft functions in follow-up were recorded. Either ex vivo URS or ex vivo pyelolithotomy was carried out after donor nephrectomy before transplantation. Informed consent was obtained from all individual participants included in the study. The study protocol was approved by the local ethics committees.
Ex vivo URS
Immediately after donor nephrectomy, the kidney was immersed in ice slush on the bench and retrograde URS was carried out under low-pressure (the irrigation bag was placed <50 cm above the kidney level) manual irrigation with normal saline, without using a wire. First, the ureter was spatulated and the distal part was stabilized with stay sutures. Then, the ureteroscope was passed through the ureter into the renal pelvis. The devices used were 6/7.5 semi-rigid ureteroscope (Richard Wolf GmbH, Knittlingen, Germany), 7.5-Fr flexible ureteroscope (Karl Storz GmbH, Tuttlingen, Germany) and 8/ 9.8-Fr 12°pediatric cystoscope (Richard Wolf GmbH). While inspecting the pelvicalyceal system, the kidney was manipulated with the free hand to obtain better visualization of the stone. In the case of a lower calyx with acute angulation that was inaccessible with a semi-rigid ureteroscope or a pediatric cystoscope, a flexible ureteroscope was used. The stone(s) identified were fragmented using holmium laser lithotripsy and removed with a nitinol basket or grasping forceps.
Ex vivo pyelolithotomy
In selected cases, such as in stones that are relatively large and clearly visible under fluoroscopy, pyelolithotomy provides a safe conduit for manipulating the surgical instruments safely without causing ureteral trauma. After placing stay sutures on the renal pelvis, pyelotomy was carried out. Under fluoroscopic guidance, Randall kidney stone forceps were used to grasp and remove the stone. In the case where the stone was not accessible by this technique, a pediatric cystoscope was used to extract the stone under direct visualization using a basket or grasping forceps. Then, the pyelotomy incision was closed using 5/0 vicryl running sutures.
Once stone clearance was confirmed, a JJ ureteral stent was placed in all patients. The urethral catheter was removed between the 5th and 7th postoperative days, and the JJ stent was removed on postoperative week 3 or 4. All recipients were followed up every 3 months by ultrasonographic evaluation. The minimum follow-up duration was 12 months.
Results
Between 2009 and 2016, 3748 living donor RTs were carried out at Medical Park Hospital, Antalya, Turkey. Of these, 13 (0.34%) donor kidneys underwent ex vivo bench surgery for the removal of asymptomatic stones. The female-to-male ratio was 1:1. The mean stone burden was 9.1 mm (range 5-15 mm). Six patients underwent ex vivo URS and seven patients underwent pyelolithotomy (Table 1) .
After initial access was obtained with a semi-rigid adult ureteroscope, a pediatric cystoscope was used in order to facilitate handling. The shorter shaft of the pediatric cystoscope enabled faster and easier access to the pelvicalyceal system by facilitating the maneuvering of the device (Fig. 1) . The mean duration of ex vivo URS procedures was 12.5 min (range 9-20 min). In one patient, the semi-rigid scope was unable to reach the stone because of the angulation of the lower calix, so a flexible ureteroscope was used to visualize the stone in the lower calix. The stone was dislodged into the renal pelvis with the help of a nitinol basket. It was then fragmented in the renal pelvis using holmium laser, and fragmented pieces were extracted with a basket. If the ureter was not wide enough to permit easy passage of the endoscope, pyelolithotomy was preferred in order to prevent the ureteral trauma that might be caused during the URS procedure.
Relatively large stones that were visible under fluoroscopy were removed by pyelolithotomy. The mean duration of pyelolithotomy was 3.1 min (range 1-8 min). In one patient, the stone could not be accessed, even though it was visible under fluoroscopy. Thus, a pediatric 8/9.8-Fr cystoscope was inserted through the pyelotomy incision. The stone was visualized in the submucosa, extracted with holmium laser and removed with a basket. None of the patients experienced any intraoperative complications. As an early postoperative complication, on postoperative day 3, one patient developed severe urinary leakage from the pyelotomy site despite the urethral catheter and the ureteral JJ stent. The leakage was repaired with primary sutures under general anesthesia (Clavien grade IIIb).
One month after transplantation, all patients had their stents removed, and the mean serum creatinine at 1-month follow up had decreased to 1.3 AE 0.5 mg/dL. The mean long-term follow-up duration was 49.6 months (range 14-101 months). None of the 13 patients who underwent ex vivo stone surgery developed stone recurrence during follow up. No ureteral obstruction was observed in the six patients who underwent ex vivo URS.
Discussion
Traditionally, nephrolithiasis is considered to be a relative contraindication to kidney transplantation (both deceased and living donor), due to the risk of future stone formation that might lead to urinary obstruction, recurrent infections and graft loss. With the development of new endourological surgical techniques that have enabled higher success and lower morbidity, minimally invasive stone surgery seems to be an effective approach to overcome these risks. In light of these developments, successful results of minimally invasive surgery used throughout different steps of the transplantation period are reported in the literature. However, no standards have been established yet for the treatment of nephrolithiasis in kidney donors. 10 Currently, if the stone in the donor kidney is <15 mm in size or potentially removable during transplant, ex vivo bench surgery is the recommended treatment option. 2 However, there is no consensus in the literature regarding whether a given stone should be managed conservatively or undergo bench surgery. In the normal population, the spontaneous passage of small ureteral stones <4 mm in size is reported to be between 76% and 98%. 11, 12 However, all of these data relate to patients with a native stone-bearing kidney and a normal contralateral kidney. Very few studies have examined the outcome of stones in transplanted kidneys. In small series with a mean follow-up period of <2 years, stone-free rates range between 60% and 100% for stones <4 mm. 3, 4 In our institution, stones <4 mm enter a follow-up protocol.
Ex vivo bench surgery for stone-bearing donor kidneys has helped reduce the morbidity rates, costs and transplant waiting times. Currently, most stone surgeries in urology practice are carried out using minimally invasive methods. Likewise, the literature shows that ex vivo bench surgery is also generally carried out using minimally invasive methods. However, there is great diversity in the methods preferred. This diversity mostly stems from the wide variety of surgical devices used.
Minimally invasive bench surgery can be categorized into two main approaches: ex vivo URS and ex vivo pyelolithotomy. The first successful ex vivo URS was reported by Rashid et al., who used a semi-rigid 6.9-Fr ureteroscope in a 10-patient series. 8 Shade et al. reported successful results with a 9.5-Fr flexible ureteroscope in stones inaccessible with a 6.9-Fr ureteroscope. 7 Pushkar et al. have accessed the stone with ex vivo URS and removed the stone with pyelotomy after manipulating it into the renal pelvis with a basket. 13 In contrast, Ganpule et al. used a 6-Fr pediatric cystoscope for ex vivo URS and achieved successful results. 6 In the present series, we used a 6/7.5-Fr semi-rigid ureteroscope for the first patient. We achieved excellent results with pediatric cystoscope, because it provided better stability and maneuverability due to its shorter shaft length.
As in ex vivo URS, pyelolithotomy is also being carried out using different techniques. Klinger et al. reported successful stone extraction with a 14.5-Fr flexible cystoscope from the pyelotomy incision in a series of patients. 10 Similarly, Ganpule et al. reported successful stone removal with a 12-Fr nephroscope from the pyelotomy incision. 6 In the present series, pyelolithotomy was successfully carried out under fluoroscopic guidance using only Randall kidney stone forceps, except for one patient.
As can be seen, stone-free success rates are similar, even though the instruments used are different. The stone-free rates reported in the literature range between 89.5% and 100%. [6] [7] [8] [9] In this case, it would be best to determine the method with the lowest morbidity instead of the method with the highest success rate. In the literature, low morbidity rates are reported both with ex vivo URS and ex vivo pyelolithotomy. Ex vivo URS poses a risk of ureteral stricture because of the potential damage that might be caused on the ischemic ureter while passing the ureteroscope.
Although most studies in the literature describe ex vivo URS as a procedure with low morbidity, Mosimann et al. reported a case of graft loss after ex vivo URS due to acute ischemia caused by a major intimal flap in the hilum. This complication was thought to occur as a result of the instrumental manipulations within the renal pelvis, leading to an injury in the adjacent artery. Thus, they suggested considering pyelotomy as an alternative to ex vivo URS, depending on the clinical conditions. output altogether hinder the spontaneous closure of the pyelotomy incision despite the JJ stent. Keeping the incision line to a minimum and closing it carefully might minimize the probability of such complications. In addition, in patients undergoing pyelotomy, taking measures such as prolonged bladder catheterization, JJ stenting, and early steroid reduction should be considered in order to avoid leakage. Another concern in such endourological procedures is the potential of renal parenchymal injury caused by pyelovenous, pyelotubular and pyelolymphatic reflux of the irrigation fluid during the procedure. 8 Although only a theory, this is a risk that cannot be overlooked. Thus, it would be best to use the lowest pressure possible during irrigation.
The duration of the operation is another matter of debate. Studies have shown that in living donor RT, a cold ischemia time up to 8 h is acceptable, as it does not jeopardize renal functions, increase acute rejection rates or affect long-term allograft survival. 15 Similarly, none of the reports on ex vivo bench surgery describe any renal damage related to the duration of the operation. Despite this, we believe that trying to keep the ischemia period as short as possible will be a wise choice. The reported durations of operation in previous studies are as follows: a mean of 28 min in the 14-patient series by Pushkar et al., 13 10-45 min in the 17-patient ex vivo URS series by Olsburgh et al.,
9 a mean of 6.5 min in a 10-patient series of ex vivo URS by Rashid et al. 8 and a mean of 6.2 min in a pyeloscopy series by Schade et al. 7 The mean pyelolithotomy duration of 3.1 min in the present study is noteworthy.
Especially for those who specialize in endourology, bench surgery is an easy-to-learn procedure, as it is easier to handle and maneuver the kidney on the back table. Thus, we believe that carrying out one procedure is sufficient for a surgeon to develop a satisfactory technique/develop adequate expertise.
Hypercalcemia, hyperparathyroidism, and hypocitraturia are metabolic factors that are known to cause stone formation, 16 and stones of metabolic origin are known to have a higher recurrence rate. 17 According to previously published series on ex vivo bench surgery, no stone recurrence was observed during the follow-up period. It has been hypothesized that the higher glomerular filtration rate and urine output that the transplanted kidney is subjected to lowers the tendency of stone recurrence. 8 We would like to emphasize how important it is to carry out metabolic assessment during donor evaluation in order to prevent the recurrence of stones after ex vivo stone surgery. The fact that none of the patients in our series suffered from stone recurrence during a mean follow-up period of 24 months supports this opinion.
Our series provides further evidence on the safety and efficacy of ex vivo URS and pyelolithotomy during living donor RT. Because of its lower morbidity and easy applicability, ex vivo URS might be preferred as the first choice. It will be wise to use a pediatric cystoscope during ex vivo URS, as this will provide better maneuvering and handling. In relatively larger stones that are visible under fluoroscopy and in case the cold ischemia time is limited, pyelolithotomy can be safely carried out. Both ex vivo URS and ex vivo pyelolithotomy seem to be stone-free in the follow up, with a low risk of recurrence.
